Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
The United States Department of Veterans Affairs currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active matter is assigned to 1 distinct examiner and 1 distinct art unit. The data indicates that the department's current patent prosecution is concentrated in this single technical field, with no other active matters reported.
SEITZ, ANTHONY JOSEPH is the busiest examiner for the portfolio, currently overseeing 1 pending office action. The presence of 1 distinct art unit shows that the department's pharmaceutical technology is being evaluated by a single specialized division. This individual handles the 1 pending office action for the portfolio.
For a practitioner, this concentration means that the prosecution strategy is focused on the 1 distinct examiner. There are no other active cases or different art units to coordinate, allowing for a direct approach. The department's immediate goals in Biotechnology & Pharmaceuticals are tied to the outcome of this single matter, making the interaction with the assigned examiner a primary focus.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PENNINGTON, KATIE LEIGH | 1 | 29.7% | +60.0% |
| SEITZ, ANTHONY JOSEPH | 1 | 68.3% | +27.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18686708 | Accelerated Protocol for the Differentiation of Podocytes from Human Pluripotent Stem Cells | PENNINGTON, KATIE LEIGH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18220137 | COMPOUNDS AND METHODS FOR SCAVENGING DICARBONYL ELECTROPHILES | SEITZ, ANTHONY JOSEPH | 60d |
| 18686708 | Accelerated Protocol for the Differentiation of Podocytes from Human Pluripotent Stem Cells | PENNINGTON, KATIE LEIGH | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18686708 | Accelerated Protocol for the Differentiation of Podocytes from Human Pluripotent Stem Cells | PENNINGTON, KATIE LEIGH | 1634 | §101§103§112 | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18220137 | COMPOUNDS AND METHODS FOR SCAVENGING DICARBONYL ELECTROPHILES | SEITZ, ANTHONY JOSEPH | 1629 | §102DPOther | Non-Final OA | 60d | Pending | Jul 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial